Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down. CEO Tony Johnson and Chief Financial and Operating Officer Kyle Kuvalanka told Fierce Biotech that the company is closing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Goldfinch Bio’s kidney disease treatment quelled rising protein levels in patients’ urine, but only in one of the two diseases being tested, according to initial data from a phase 2 trial.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Little in the way of innovation has made news in the past 20 years. Cambridge, Mass.-based Goldfinch Bio aspires to change that. The startup is announcing today it has raised $55 million in a ...

Karuna Therapeutics, Inc. KRTX announced a definitive agreement with Goldfinch Bio assignment estate to acquire global development, manufacturing and commercialization rights to the latter's ...

The new Karuna assets come from startup Goldfinch Bio, which is shutting down. According to financial terms announced Thursday, Boston-based Karuna is paying $15 million up front for both small ...

Please provide your email address to receive an email when new articles are posted on . Biopharmaceutical company Karuna Therapeutics has announced an exclusive license agreement with biotech firm ...

Goldfinch Bio, located in Kendall Square, will focus on developing kidney disease drugs that use precision medicine — personalizing treatments to fit patients based on their genetics. Fresh off ...